Immunocore (IMCR)

Immunocore Limited • Immunocore LLC • Immunocore Commercial LLC • Immunocore Ireland Limited Ireland • Immunocore GmbH • Immunocore Nominees Limited ...

IMCR stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

8-K

Submission of Matters to a Vote of Security Holders

15 May 25

S-8

Registration of securities for employees

7 May 25

8-K

Immunocore reports first quarter financial results and provides a business update

7 May 25

Annual report to shareholders

4 Apr 25

Prospectus with selling stockholder info

17 Mar 25

POSASR

Automatic shelf registration (post-effective amendment)

17 Mar 25

Transcripts

View all

IMCR

Earnings call transcript

2024 Q4

26 Feb 25

IMCR

Earnings call transcript

2024 Q2

8 Aug 24

IMCR

Earnings call transcript

2023 Q4

28 Feb 24

IMCR

Earnings call transcript

2023 Q2

10 Aug 23

IMCR

Earnings call transcript

2023 Q2

10 Aug 23

IMCR

Earnings call transcript

2022 Q4

1 Mar 23

IMCR

Earnings call transcript

2022 Q2

10 Aug 22

Latest ownership filings

View all

T. Rowe Price Investment Management, Inc.

14 May 25

SC 13G/A

WELLINGTON MANAGEMENT GROUP LLP

12 May 25

JULIAN BAKER

19 Mar 25

Financial summary

Financial statements Chart IMCR financial data

Quarter (USD)	Mar 25	Dec 24	Sep 24	Jun 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	476.85 mm	476.85 mm	476.85 mm	476.85 mm	476.85 mm	476.85 mm
Cash burn (monthly)	(no burn)	29.66 mm	(no burn)	3.60 mm	(no burn)	(no burn)
Cash used (since last report)	n/a	76.78 mm	n/a	9.33 mm	n/a	n/a
Cash remaining	n/a	400.06 mm	n/a	467.51 mm	n/a	n/a
Runway (months of cash)	n/a	13.5	n/a	129.7	n/a	n/a

Beta Read what these cash burn values mean

Financial data from Immunocore earnings reports.

Institutional ownership, Q4 2024

IMCR institutional ownership history Ownership history

94.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	116	129	-10.1%
Opened positions	14	18	-22.2%
Closed positions	27	28	-3.6%
Increased positions	35	47	-25.5%
Reduced positions	43	36	+19.4%

13F shares	Current	Prev Q	Change
Total value	1.06 tn	1.12 tn	-5.0%
Total shares	47.51 mm	47.36 mm	+0.3%
Total puts	38.70 k	450.90 k	-91.4%
Total calls	75.50 k	192.40 k	-60.8%
Total put/call ratio	0.5	2.3	-78.1%

Largest owners	Shares	Value	Change
T. Rowe Price Investment Management	6.70 mm	$197.66 mm	+3.1%
Wellington Management	6.62 mm	$195.20 bn	-6.1%
RTW Investments	4.87 mm	$143.66 bn	0.0%
FMR	4.82 mm	$142.12 bn	-0.4%
Primecap Management	2.67 mm	$78.72 bn	+8.0%
T. Rowe Price	2.19 mm	$64.53 mm	+1.4%
Malin Life Sciences	2.11 mm	$111.40 mm	0.0%
Tang Capital Management	1.56 mm	$45.89 bn	+40.7%
Baker Bros. Advisors	1.52 mm	$44.70 bn	0.0%
General Atlantic	1.26 mm	$37.22 bn	0.0%

Largest transactions	Shares	Bought/sold	Change
Kynam Capital Management	1.23 mm	+1.23 mm	NEW
C Citigroup	632.94 k	+616.91 k	+3848.0%
BlackRock	272.78 k	-600.83 k	-68.8%
Deep Track Capital	519.38 k	+519.38 k	NEW
Tang Capital Management	1.56 mm	+450.00 k	+40.7%
Wellington Management	6.62 mm	-431.78 k	-6.1%
Point72 Asset Management	403.30 k	+403.30 k	NEW
Polar Capital	114.02 k	-387.73 k	-77.3%
MS Morgan Stanley	130.64 k	-274.18 k	-67.7%
BNP Paribas Asset Management Holding	161.29 k	-265.86 k	-62.2%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

IMCR insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
15 May 25	Baker Bros. Advisors	Non-Qualified Share Option Ordinary Shares	Grant	Acquire A	Yes	No	29.06	26,198	761.31 k	26,198
15 May 25	Baker Bros. Advisors	Non-Qualified Share Option Ordinary Shares	Grant	Acquire A	Yes	No	29.06	26,198	761.31 k	26,198
15 May 25	Roy Steven Herbst	Share Option Ordinary Shares	Grant	Acquire A	No	No	29.06	26,198	761.31 k	26,198
15 May 25	Kristine Peterson	Share Option Ordinary Shares	Grant	Acquire A	No	No	29.06	26,198	761.31 k	26,198
15 May 25	Siddharth Kaul	Share Option Ordinary Shares	Grant	Acquire A	No	No	29.06	26,198	761.31 k	26,198
15 May 25	John Irving Bell	Share Option Ordinary Shares	Grant	Acquire A	No	No	29.06	26,198	761.31 k	26,198

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Demystifying Immunocore Holdings: Insights From 9 Analyst Reviews

2 Jun 25

HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target

2 Jun 25

HC Wainwright & Co. analyst Patrick Trucchio reiterates Immunocore Holdings (NASDAQ:IMCR) with a Buy and maintains $100 price target.

Oppenheimer Maintains Outperform on Immunocore Holdings, Raises Price Target to $86

8 May 25

Oppenheimer analyst Jeff Jones maintains Immunocore Holdings (NASDAQ:IMCR) with a Outperform and raises the price target from $85 to $86.

Immunocore Hldgs Q1 GAAP EPS $0.10 Beats $(0.39) Estimate, Sales $93.88M Beat $88.52M Estimate

7 May 25

JP Morgan Maintains Overweight on Immunocore Holdings, Lowers Price Target to $50

14 Apr 25